Document is current
Any future updates will be listed below
-
Authors
Jensen, Christian Møller
Marandi, Ramtin Z.
Costa, Junia C.
Zetner, Dennis
Berger, Siv Mari Sollien
Niemann, Carsten U.
Ostrowski, Sisse R.
Reekie, Joanne
Holten, Birgit
Kalhauge, Anna
Ledergerber, Bruno
Lundgren, Jens
Helleberg, Marie
Moestrup, Kasper S.
-
Funding
Funding for this research was provided by:
Rigshospitalet (E-23641-03)
Danish National Research Foundation (126)
Danish National Research Foundation (126)
The Danish Ministry of Higher Education and Science (0238-00006B)
The Danish Ministry of Higher Education and Science (0238-00006B)
The Novo Nordisk Foundation (NNF20SA0063191)
- License Information
-
More Information
Article History
Received: 13 September 2025
Accepted: 4 February 2026
First Online: 11 February 2026
Declarations
:
: CUN received research funding and/or consultancy fees from Abbvie, AstraZeneca, Janssen, Beigene, Genmab, Octapharma, Takeda, MSD, Lilly, CSL Behring, Galapagos, Synamics, Novo Nordisk Foundation. No further financial or non-financial competing interests to declare.
: The study was approved by the Regional Ethical Committee of the Capital Region of Denmark (H-20026502) and the Data Protection Agency (P-2020-426), and the requirement for informed consent was waived for this study. The study was done in accordance with relevant guidelines, regulations and the Declaration of Helsinki.
